LH up +0.04% percent Today $LH High is at 101.82 a
Post# of 53482
Posted On: 11/19/2014 2:58:20 PM
LH up +0.04% percent Today $LH High is at 101.82 and the Low 100.81 with current volume of 136,637.
Recent News posted below.
Laboratory Corporation of America Holdin LH other info.
http://investorshangout.com/Laboratory-Corpor...-LH-51679/
LH Laboratory Corporation of America Holdin Recent Headline News
Laboratory Corp of America Holdings Set to Possibly Pullback After Yesterday's Rally of 1.10%
Comtex SmarTrend(R) - Tue Nov 18, 5:15PM CST
Laboratory Corp of America Holdings (NYSE:LH) traded in a range yesterday that spanned from a low of $100.00 to a high of $101.34. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $100.51 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LH: 101.50 (+0.32)
Covance (CVD) Sellout Decision to LabCorp: A Strategic Fit? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 3:10PM CST
On Nov 18, we issued an updated research report on Covance Inc. (CVD).
Q: 57.66 (+0.33), LH: 101.50 (+0.32), SNY: 48.11 (-0.25), CVD: 100.92 (+0.12)
LabCorp Shows Strength on Covance Buyout Plan, Robust Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 3:34PM CST
On Nov 17, 2014, we issued an updated research report on Laboratory Corporation of America Holdings (LH).
ABC: 89.24 (-0.52), BCR: 166.45 (-0.91), CAH: 79.73 (-1.28), UNH: 96.88 (-1.31), LH: 101.50 (+0.32), BMY: 58.58 (-0.12)
Laboratory Corp of America Holdings Earnings Review: 20 Days after Announcement Shares Down 8.1% (LH)
Comtex SmarTrend(R) - Mon Nov 17, 8:00AM CST
When Laboratory Corp of America Holdings (NYSE:LH) reported earnings two weeks ago on October 28th, 2014, analysts, on average, expected the company to report earnings of $1.75 on sales of $1.5 billion. Laboratory Corp of America Holdings actually reported earnings of $1.80 per share on sales of $1.6 billion, beating EPS estimates by $0.05 and beating revenue estimates by $48.3 million. Shares of Laboratory Corp of America Holdings have slipped from $107.51 to $98.84, representing a loss of 8.1%, since the company reported earnings 20 days ago.
LH: 101.50 (+0.32)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Covance, Inc. in Connection with the Sale of the Company
Business Wire - Mon Nov 17, 6:00AM CST
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Covance, Inc. ("Covance" or the "Company"
(NYSE:CVD) relating to the proposed acquisition by Laboratory Corporation of America Holdings. ("LabCorp" .
LH: 101.50 (+0.32), CVD: 100.92 (+0.12)
Look for Shares of Laboratory Corp of America Holdings to Potentially Rebound after Yesterday's 1.13% Sell Off
Comtex SmarTrend(R) - Thu Nov 13, 4:33PM CST
Laboratory Corp of America Holdings (NYSE:LH) traded in a range yesterday that spanned from a low of $98.80 to a high of $100.51. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $99.01 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LH: 101.50 (+0.32)
Watch for Laboratory Corp of America Holdings to Potentially Rebound After Falling 1.13% Yesterday
Comtex SmarTrend(R) - Thu Nov 13, 4:33PM CST
Laboratory Corp of America Holdings (NYSE:LH) traded in a range yesterday that spanned from a low of $98.80 to a high of $100.51. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $99.01 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LH: 101.50 (+0.32)
Global Preimplantation Genetic Diagnosis (PGD for Chromosomal Aberrations, Aneuploidy Screening, Gender Selection, Single Gene Disorders, HLA Typing and X-linked Diseases) Market - Trends and Forecast to 2020
M2 - Tue Nov 11, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/sm76mf/preimplantation) has announced the addition of the "Preimplantation Genetic Diagnosis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Since the last two decades, preimplantation genetic diagnosis (PGD) has been used to detect chromosomal aneuploidy in low prognosis patients who undergo in-vitro fertilization (IVF). PGD is now being used to detect a broader range of indications due to advancements in the medical technology. These indications include chromosomal aberrations, genetic abnormalities, gender selection, HLA typing, X-linked diseases and single gene diseases. Demand for PGD is continuously increasing in patients who undergo IVF in the hope that it would improve the probability of live birth and reduce the chances of disabilities and genetic disorders in the offspring. This report provides in-depth analysis of the preimplantation genetic diagnosis market and its test types across various regions. Stakeholders in the report include diagnostic laboratories that provide PGD services, companies involved in the production of diagnosis kits and sequencers for PGD, and prospective market players planning to enter the market. The report comprises executive summary, which offers a market snapshot that covers the overall information about various types of tests in the PGD market. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Preimplantation Genetic Diagnosis Market Overview Chapter 4 Global Preimplantation Genetic Diagnosis Market, by Test Type Chapter 5 Preimplantation Genetic Diagnosis Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles Companies Mentioned: - Genea Ltd. - Genesis Genetics - Illumina, Inc. - Laboratory Corporation of America Holdings (LabCorp) - Natera, Inc. - PerkinElmer, Inc. - Quest Diagnostics, Inc. - Reproductive Genetics Institute - Reprogenetics LLC For more information visit http://www.researchandmarkets.com/research/sm...plantation
DGX: 63.57 (-0.52), LH: 101.50 (+0.32), ILMN: 189.41 (-0.44), PKI: 43.74 (-0.12)
Merger Arbitrage Mondays - November 10, 2014
Asif Suria - Seeking Alpha - Mon Nov 10, 11:24AM CST
Merger Activity increased last week with six new mergers announced and one deal closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: ...
ESYS: 17.32 (+0.01), HBNK: 19.95 (-0.38), LNN: 86.73 (+0.93), BHLB: 25.40 (-0.41), SAPE: 24.64 (-0.01), XWES: 5.45 (unch), ENOC: 14.87 (-0.28), LH: 101.50 (+0.32), STL: 13.54 (-0.26), HVB: 25.27 (-0.70), BAGL: 20.23 (-0.01), CVD: 100.92 (+0.12)
Laboratory Corporation: Strategic Acquisition Of Covance Appears To Be A Wealth Transfer
The Value Investor - at Seeking Alpha - Sat Nov 08, 7:10AM CST
LH: 101.50 (+0.32)
SmarTrend Watching for Potential Rebound in Shares of Laboratory Corp of America Holdings After 2.36% Loss
Comtex SmarTrend(R) - Fri Nov 07, 3:59PM CST
Laboratory Corp of America Holdings (NYSE:LH) traded in a range yesterday that spanned from a low of $100.05 to a high of $102.91. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $100.12 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LH: 101.50 (+0.32)
Laboratory Corp of America Holdings Set to Possibly Rebound After Yesterday's Selloff of 2.36%
Comtex SmarTrend(R) - Fri Nov 07, 3:59PM CST
Laboratory Corp of America Holdings (NYSE:LH) traded in a range yesterday that spanned from a low of $100.05 to a high of $102.91. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $100.12 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LH: 101.50 (+0.32)
COVANCE, INC. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Covance, Inc. Over the Proposed Sale of the Company to Laboratory Corporation of America Holdings - CVD
PR Newswire - Thu Nov 06, 3:53PM CST
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Covance, Inc. ("Covance" or the "Company" (NYSE: CVD) for potential breaches of fiduciary duties in connection with the sale of the Company to Laboratory Corp. of America Holdings in a cash and stock deal for approximately $5.6 billion. The Company's stockholders will receive $75.76 in cash and 0.2686 shares of LabCorp common stock for each share of Covance common stock they own.
LH: 101.50 (+0.32), CVD: 100.92 (+0.12)
Quarterly Financial Results, Acquisition Agreement, and Accelerated Drug Approval - Research Reports on Gilead, Covance, Laboratory Corp., Pfizer and AbbVie
PR Newswire - Thu Nov 06, 8:30AM CST
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Covance Inc. (NYSE: CVD), Laboratory Corp. of America Holdings (NYSE: LH), Pfizer Inc. (NYSE: PFE) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7736-100free.
GILD: 101.99 (-1.72), PFE: 30.31 (-0.28), LH: 101.50 (+0.32), ABBV: 65.35 (-0.70), CVD: 100.92 (+0.12)
COVANCE INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Business Wire - Wed Nov 05, 11:05AM CST
Rigrodsky & Long, P.A.:
LH: 101.50 (+0.32), CVD: 100.92 (+0.12)
Covance to be Acquired by LabCorp, Shares Surge 25.9% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:15PM CST
Drug-development company Covance Inc.'s (CVD) share price jumped 25.9% to close at $110.57 yesterday
BEAT: 8.16 (-0.31), LH: 101.50 (+0.32), ICLR: 53.74 (+0.41), CVD: 100.92 (+0.12)
Robbins Arroyo LLP: Acquisition of Covance Inc. (CVD) by Laboratory Corporation of America Holdings (LH) May Not Be in Shareholders' Best Interests
PR Newswire - Tue Nov 04, 1:30PM CST
Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Covance Inc. (NYSE: CVD) by Laboratory Corporation of America Holdings (NYSE: LH). On November 3, 2014, the two companies announced the signing of a definitive merger agreement pursuant to which Covance shareholders will receive 0.2686 Laboratory Corporation shares and $75.76 per share in cash and for each share of Covance owned, for a total consideration of $105.12.
LH: 101.50 (+0.32), CVD: 100.92 (+0.12)
Covance Q3 Guidance Narrowed on In-Line Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 1:20PM CST
Covance (CVD) reported mixed third-quarter 2014 financial results, with the bottom line exceeding the Zacks Consensus Estimate and the top line missing the same.
BEAT: 8.16 (-0.31), LH: 101.50 (+0.32), ICLR: 53.74 (+0.41), CVD: 100.92 (+0.12)
Recent News posted below.
Laboratory Corporation of America Holdin LH other info.
http://investorshangout.com/Laboratory-Corpor...-LH-51679/
LH Laboratory Corporation of America Holdin Recent Headline News
Laboratory Corp of America Holdings Set to Possibly Pullback After Yesterday's Rally of 1.10%
Comtex SmarTrend(R) - Tue Nov 18, 5:15PM CST
Laboratory Corp of America Holdings (NYSE:LH) traded in a range yesterday that spanned from a low of $100.00 to a high of $101.34. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $100.51 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LH: 101.50 (+0.32)
Covance (CVD) Sellout Decision to LabCorp: A Strategic Fit? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 3:10PM CST
On Nov 18, we issued an updated research report on Covance Inc. (CVD).
Q: 57.66 (+0.33), LH: 101.50 (+0.32), SNY: 48.11 (-0.25), CVD: 100.92 (+0.12)
LabCorp Shows Strength on Covance Buyout Plan, Robust Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 3:34PM CST
On Nov 17, 2014, we issued an updated research report on Laboratory Corporation of America Holdings (LH).
ABC: 89.24 (-0.52), BCR: 166.45 (-0.91), CAH: 79.73 (-1.28), UNH: 96.88 (-1.31), LH: 101.50 (+0.32), BMY: 58.58 (-0.12)
Laboratory Corp of America Holdings Earnings Review: 20 Days after Announcement Shares Down 8.1% (LH)
Comtex SmarTrend(R) - Mon Nov 17, 8:00AM CST
When Laboratory Corp of America Holdings (NYSE:LH) reported earnings two weeks ago on October 28th, 2014, analysts, on average, expected the company to report earnings of $1.75 on sales of $1.5 billion. Laboratory Corp of America Holdings actually reported earnings of $1.80 per share on sales of $1.6 billion, beating EPS estimates by $0.05 and beating revenue estimates by $48.3 million. Shares of Laboratory Corp of America Holdings have slipped from $107.51 to $98.84, representing a loss of 8.1%, since the company reported earnings 20 days ago.
LH: 101.50 (+0.32)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Covance, Inc. in Connection with the Sale of the Company
Business Wire - Mon Nov 17, 6:00AM CST
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Covance, Inc. ("Covance" or the "Company"
(NYSE:CVD) relating to the proposed acquisition by Laboratory Corporation of America Holdings. ("LabCorp" . LH: 101.50 (+0.32), CVD: 100.92 (+0.12)
Look for Shares of Laboratory Corp of America Holdings to Potentially Rebound after Yesterday's 1.13% Sell Off
Comtex SmarTrend(R) - Thu Nov 13, 4:33PM CST
Laboratory Corp of America Holdings (NYSE:LH) traded in a range yesterday that spanned from a low of $98.80 to a high of $100.51. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $99.01 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LH: 101.50 (+0.32)
Watch for Laboratory Corp of America Holdings to Potentially Rebound After Falling 1.13% Yesterday
Comtex SmarTrend(R) - Thu Nov 13, 4:33PM CST
Laboratory Corp of America Holdings (NYSE:LH) traded in a range yesterday that spanned from a low of $98.80 to a high of $100.51. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $99.01 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LH: 101.50 (+0.32)
Global Preimplantation Genetic Diagnosis (PGD for Chromosomal Aberrations, Aneuploidy Screening, Gender Selection, Single Gene Disorders, HLA Typing and X-linked Diseases) Market - Trends and Forecast to 2020
M2 - Tue Nov 11, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/sm76mf/preimplantation) has announced the addition of the "Preimplantation Genetic Diagnosis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Since the last two decades, preimplantation genetic diagnosis (PGD) has been used to detect chromosomal aneuploidy in low prognosis patients who undergo in-vitro fertilization (IVF). PGD is now being used to detect a broader range of indications due to advancements in the medical technology. These indications include chromosomal aberrations, genetic abnormalities, gender selection, HLA typing, X-linked diseases and single gene diseases. Demand for PGD is continuously increasing in patients who undergo IVF in the hope that it would improve the probability of live birth and reduce the chances of disabilities and genetic disorders in the offspring. This report provides in-depth analysis of the preimplantation genetic diagnosis market and its test types across various regions. Stakeholders in the report include diagnostic laboratories that provide PGD services, companies involved in the production of diagnosis kits and sequencers for PGD, and prospective market players planning to enter the market. The report comprises executive summary, which offers a market snapshot that covers the overall information about various types of tests in the PGD market. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Preimplantation Genetic Diagnosis Market Overview Chapter 4 Global Preimplantation Genetic Diagnosis Market, by Test Type Chapter 5 Preimplantation Genetic Diagnosis Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles Companies Mentioned: - Genea Ltd. - Genesis Genetics - Illumina, Inc. - Laboratory Corporation of America Holdings (LabCorp) - Natera, Inc. - PerkinElmer, Inc. - Quest Diagnostics, Inc. - Reproductive Genetics Institute - Reprogenetics LLC For more information visit http://www.researchandmarkets.com/research/sm...plantation
DGX: 63.57 (-0.52), LH: 101.50 (+0.32), ILMN: 189.41 (-0.44), PKI: 43.74 (-0.12)
Merger Arbitrage Mondays - November 10, 2014
Asif Suria - Seeking Alpha - Mon Nov 10, 11:24AM CST
Merger Activity increased last week with six new mergers announced and one deal closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: ...
ESYS: 17.32 (+0.01), HBNK: 19.95 (-0.38), LNN: 86.73 (+0.93), BHLB: 25.40 (-0.41), SAPE: 24.64 (-0.01), XWES: 5.45 (unch), ENOC: 14.87 (-0.28), LH: 101.50 (+0.32), STL: 13.54 (-0.26), HVB: 25.27 (-0.70), BAGL: 20.23 (-0.01), CVD: 100.92 (+0.12)
Laboratory Corporation: Strategic Acquisition Of Covance Appears To Be A Wealth Transfer
The Value Investor - at Seeking Alpha - Sat Nov 08, 7:10AM CST
LH: 101.50 (+0.32)
SmarTrend Watching for Potential Rebound in Shares of Laboratory Corp of America Holdings After 2.36% Loss
Comtex SmarTrend(R) - Fri Nov 07, 3:59PM CST
Laboratory Corp of America Holdings (NYSE:LH) traded in a range yesterday that spanned from a low of $100.05 to a high of $102.91. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $100.12 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LH: 101.50 (+0.32)
Laboratory Corp of America Holdings Set to Possibly Rebound After Yesterday's Selloff of 2.36%
Comtex SmarTrend(R) - Fri Nov 07, 3:59PM CST
Laboratory Corp of America Holdings (NYSE:LH) traded in a range yesterday that spanned from a low of $100.05 to a high of $102.91. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $100.12 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LH: 101.50 (+0.32)
COVANCE, INC. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Covance, Inc. Over the Proposed Sale of the Company to Laboratory Corporation of America Holdings - CVD
PR Newswire - Thu Nov 06, 3:53PM CST
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Covance, Inc. ("Covance" or the "Company"
(NYSE: CVD) for potential breaches of fiduciary duties in connection with the sale of the Company to Laboratory Corp. of America Holdings in a cash and stock deal for approximately $5.6 billion. The Company's stockholders will receive $75.76 in cash and 0.2686 shares of LabCorp common stock for each share of Covance common stock they own. LH: 101.50 (+0.32), CVD: 100.92 (+0.12)
Quarterly Financial Results, Acquisition Agreement, and Accelerated Drug Approval - Research Reports on Gilead, Covance, Laboratory Corp., Pfizer and AbbVie
PR Newswire - Thu Nov 06, 8:30AM CST
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Covance Inc. (NYSE: CVD), Laboratory Corp. of America Holdings (NYSE: LH), Pfizer Inc. (NYSE: PFE) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7736-100free.
GILD: 101.99 (-1.72), PFE: 30.31 (-0.28), LH: 101.50 (+0.32), ABBV: 65.35 (-0.70), CVD: 100.92 (+0.12)
COVANCE INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Business Wire - Wed Nov 05, 11:05AM CST
Rigrodsky & Long, P.A.:
LH: 101.50 (+0.32), CVD: 100.92 (+0.12)
Covance to be Acquired by LabCorp, Shares Surge 25.9% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:15PM CST
Drug-development company Covance Inc.'s (CVD) share price jumped 25.9% to close at $110.57 yesterday
BEAT: 8.16 (-0.31), LH: 101.50 (+0.32), ICLR: 53.74 (+0.41), CVD: 100.92 (+0.12)
Robbins Arroyo LLP: Acquisition of Covance Inc. (CVD) by Laboratory Corporation of America Holdings (LH) May Not Be in Shareholders' Best Interests
PR Newswire - Tue Nov 04, 1:30PM CST
Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Covance Inc. (NYSE: CVD) by Laboratory Corporation of America Holdings (NYSE: LH). On November 3, 2014, the two companies announced the signing of a definitive merger agreement pursuant to which Covance shareholders will receive 0.2686 Laboratory Corporation shares and $75.76 per share in cash and for each share of Covance owned, for a total consideration of $105.12.
LH: 101.50 (+0.32), CVD: 100.92 (+0.12)
Covance Q3 Guidance Narrowed on In-Line Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 1:20PM CST
Covance (CVD) reported mixed third-quarter 2014 financial results, with the bottom line exceeding the Zacks Consensus Estimate and the top line missing the same.
BEAT: 8.16 (-0.31), LH: 101.50 (+0.32), ICLR: 53.74 (+0.41), CVD: 100.92 (+0.12)
(0)
(0)Scroll down for more posts ▼